AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02533817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary sugar
Description: This study examined the effect of high intakes of fructose compared to high intakes of glucose in a randomized crossover design. The treatment was in replacement of 20% of the daily caloric requirements for either fructose or glucose for each individual.
Study NCT02324608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT02324608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03057990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine will be administered 50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
Study NCT04610541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir-HU
Description: Remdesivir-HU 100 mg concentrate for solution for infusion
Study NCT03303846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo high risk breast cancer screening MRI
Study NCT03303846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection
Study NCT03303846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02969239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: bolus administered norepinephrine 5mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
Study NCT02969239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: bolus administered phenylephrine 100mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
Study NCT04084184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1812
Description: Dapagliflozin (Forxiga) 10mg
Study NCT04084184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1602
Description: Dapagliflozin 10mg
Study NCT01239043 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide
Description: 0.5 mL, Subcutaneous
Study NCT01239043 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study NCT00112827 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow irradiation
Description: Undergo irradiation
Study NCT00112827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00112827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo transplantation
Study NCT00112827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study NCT00112827 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies
Study NCT00112827 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies
Study NCT00112827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00112827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: Undergo transplantation
Study NCT00112827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT02874924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: treatment
Study NCT02874924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control
Study NCT02874924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: No placebo control in this substudy group
Study NCT03568487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive scapula-focused approach
Description: scapula-focused approach with exercises, 3 x 20 min training per week for 4 weeks
Study NCT03568487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Therapy
Description: not have any physical training but is encouraged to stay active as usual.
Study NCT00692276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superion™ Interspinous Spacer
Description: Implantation of interspinous process spacer to treat lumbar spinal stenosis
Study NCT00692276 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: X-STOP® IPD® Device
Description: Implantation of interspinous process spacer to treat lumbar spinal stenosis
Study NCT01072760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: K wire
Description: Mallet finger treatment
Study NCT01033422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
Study NCT01033422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for
Description: Matching placebo tablets orally every 12 hours for 16 weeks
Study NCT04158232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Method
Description: treatment of mature teeth with apical periodontitis
Study NCT04158232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Method
Description: treatment of mature teeth with apical periodontitis
Study NCT02935725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose AUT00206 800mg
Study NCT02935725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose AUT00206 2000 mg
Study NCT02935725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02935725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT02935725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Study NCT02935725 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02313376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAP3KO
Description: GAP3KO administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes under controlled conditions.
Study NCT04782336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sample Collection
Description: Sample Collection - Adult Population:~* Two (2) Nasal AND/OR~* Two (2) Throat Swabs AND/OR~* One (1) Saliva Sample~Sample Collection - Paediatric Population:~* Two (2) Nasal OR~* Two (2) Throat Swabs AND/OR~* One (1) Saliva Sample
Study NCT00307684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: double blind placebo
Description: matching placebo tablets once daily for 4 weeks
Study NCT00307684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: double blind PR OROS methylphenidate
Description: 18, 36, 54,72 or 90 mg/day once daily for 4 weeks
Study NCT00307684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open label PR OROS methylphenidate
Description: Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
Study NCT04023500 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interview vs. prevailing education
Description: In intervention group dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients.~In control croup dental hygienist defined patients educational needs and gave direct instructions how to change behaviour and self-care.
Study NCT02828540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT047 High-dose group
Description: HT047 2250mg, three times a day dosing schedule, 3 tablets per dose
Study NCT02828540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT047 Low-dose group
Description: HT047 1500mg, three times a day dosing schedule, 3 tablets per dose
Study NCT02828540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo having the same appearance as HT047 Tab. 250mg
Study NCT00951002 — intervention group
Intervention type: PROCEDURE
Intervention: acellular dermal matrix plug
Description: anal fistula treated with human acellular dermal matrix plug
Study NCT04488627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional transthoracic echocardiographic examination at the intensive care unit.
Description: Conventional transthoracic echocardiographic examination at the intensive care unit targeted to inferior caval vein examination from different views.
Study NCT05243238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary supplement flavonoids
Description: patients were allocated to receive either hesperidin, diosmin, or combination of both and the fourth group was assigned as a control group without intervention
Study NCT05861700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: B) Dbic 35 -30 mmol/L C) Dbic 30- 35 mmol/L
Description: A change Dbic in a middle of hemodialysis
Study NCT05861700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: C) Dbic 30 -35 mmol/L B) Dbic 35- 30 mmol/L
Description: A change Dbic in a middle of hemodialysis
Study NCT02587988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1302
Study NCT02587988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0904
Study NCT02587988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for HCP1302)
Study NCT02587988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for HGP0904)
Study NCT04033666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal cannula
Description: The HFNC will be instituted therapy with high-flow nasal cannula with dosage and cannula calculated according to the child's weight, ranging from 2 l / min to 30 l / min. The therapy will begin with diaphragmatic exercises 3x10 breaths and after high-flow therapy with nasal cannula for 45 minutes, after which will be performed the vital signs evaluations and Peak Flow, HRV, FEV1.
Study NCT04033666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIV Noninvasive Ventilation
Description: The Therapy consisted of 3x10 diaphragmatic re-education exercises after a Bipap device was coupled in bipedal mode with parameters Ipap 12 cm H2O and Epap 8 cm H2O, for 45 minutes, according to the patient's tolerance, with Full face facial mask. After therapy evaluated vital signs and measures of Peak Flow, HRV, FEV1.
Study NCT03292432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TERA Intervention (TERA)
Description: A sequence of adherence support strategies implemented at care visits and as needed on the basis of EDM data. Components include: (1) remote education/preparation with an adherence coach conducted with VSee software (video conferencing) at site at baseline, week 4 and week 12; (2) one-way text alert at dose time when bottle has not yet been opened for that dosing window (users can disable this on request); (3) missed dose two-way outreach text asking What's the plan? which gets sent to both the participant's phone and a study phone; and (4) implementation of the coach-outreach (phone, text, remote counseling) triggered by missed doses or as a check-in to inquire about the well-being of the youth (once per week when no other contact with coach occurred the week prior).
Study NCT03292432 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Cell-phone reminders, patient-education, adherence planning (medication management), and checking-in on adherence at clinical care visits, as well as Viral load (VL) monitoring with patient feedback on VL, are used at sites. Less common, but available as a general service at some sites, on several websites, and at many pharmacies, youth may also receive text messages at dose times, for appointment reminders, and for refill reminders.
Study NCT02875886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: Combined with hydrochlorothiazide
Study NCT02875886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Combined with amiloride
Study NCT02875886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-sodium diet
Study NCT04461093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure wristband and Palanosetron
Description: Group 1 Patients with odd numbers labelled form will be Group I patients. They will receive intravenous dexamethasone 8mg during induction. Acupressure P6 wristband is applied after induction and removed prior to emergence to maintain blinding. Intravenous ondansetron 4mg is given prior to skin closure.~Group 11 Patients with even numbers labelled form will be Group II patients who will receive intravenous palonosetron 0.075mg during induction.
Study NCT04461093 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure wristband and Palanosetron
Description: Group 1 Patients with odd numbers labelled form will be Group I patients. They will receive intravenous dexamethasone 8mg during induction. Acupressure P6 wristband is applied after induction and removed prior to emergence to maintain blinding. Intravenous ondansetron 4mg is given prior to skin closure.~Group 11 Patients with even numbers labelled form will be Group II patients who will receive intravenous palonosetron 0.075mg during induction.
Study NCT05526079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watchfuf waiting
Description: Careful review of patient response with the hope of avoiding radical surgery.
Study NCT02557529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: 12 weeks supervised resistance training program. Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
Study NCT02557529 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical activity
Description: Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
Study NCT02557529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
Study NCT02557529 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet diary
Description: Weekly diet diary during the 12-weeks intervention
Study NCT02557529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet diary
Description: Weekly diet diary during the 12-weeks intervention
Study NCT03898037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss intervention
Description: weight loss intervention under the guidance of a dietitian, including: restricted energy balanced diet, aerobic exercise, etc.
Study NCT03898037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin intervention
Description: metformin intervention with a starting dose of 0.5g bid, and the dose will be adjusted by doctors according to the patient's insulin level and adverse events.
Study NCT02704793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral 1 Hz Cerebellar rTMS
Description: 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere every day for 5 consecutive days.
Study NCT02704793 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (electrical stimulation)
Description: 900 pulses of 1 Hz electrical stimulation (less than 3 mili amperes) delivered over each cerebellar hemisphere every day for 5 consecutive days.
Study NCT03025685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRUST technique
Description: A soft hydrophilic wire easily pass through the invisible small vessels in the distal parts of a coronary artery into a heart cavity. It is necessary to pass a wire softly and forward as deep as possible. Quite often the wire goes through the left ventricle to aorta arch, and sometimes distal soft tip can be visible in a descending aorta. Thus the stiffest part of the wire become staying on all length of artery, straightening bends and giving the maximum support. After that balloons and stents can be delivered more easily
Study NCT03025685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anchoring Technique
Description: A standard endovascular technique of coronary wire support improvement
Study NCT03025685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stenting
Description: A standard endovascular procedure of percutaneous coronary intervention with coronary stenting
Study NCT03025685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Description: A standard endovascular procedure of percutaneous coronary intervention with coronary stenting
Study NCT02876159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2016-2017 Influenza Vaccine
Description: Quadrivalent influenza A/Hemagglutinin Type 1 (H1N1), A/Influenza A virus subtype (A/H3N2) H3N2,and B virus vaccine for Intramuscular (IM) use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.
Study NCT03526276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACP paste
Description: Children will brush their teeth with CPP-ACP paste twice daily.
Study NCT03526276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: Children will brush their teeth with fluoridated toothpaste twice daily
Study NCT03526276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Both (Fluoride and CPP-ACP)
Description: Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after toothbrushing, twice daily.
Study NCT02553967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional MRI
Description: Functional MRI
Study NCT04686201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Mobile Application
Description: incorporating mobile application usage in managing diabetes mellitus patient in health clinics
Study NCT04539535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Movements Assessment on two different surfaces in infants with DS and typically infants on the same day
Description: Different surface
Study NCT02235831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A MF contact lenses (DACP MF)
Description: Multifocal contact lenses in Low, Medium, High Add
Study NCT02235831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A MF contact lenses (DACP MF)
Description: Multifocal contact lenses in Low, Medium, High Add
Study NCT02235831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A single vision contact lenses (DACP)
Study NCT02235831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A single vision contact lenses (DACP)
Study NCT02934256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.
Study NCT01283204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP
Description: \<Every 3 weeks>~1. Day 1\~14 : TS-1 80mg/m2/day (PO),~2. Day 1 : CDDP 60mg/m2/day IVF 2hours,~3. Day 15\~21 : Rest.
Study NCT01283204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FL/Tax
Description: \<Every q 3 weeks>~1. Day1 : Paclitaxel 175mg/m2 IVF for 2hours~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours
Study NCT01283204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FL/Doc
Description: \<Every q 3 weeks>~1. Day1 : Docetaxel 75mg/m2 IVF for 1hour~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours
Study NCT01283204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: \<Every q 2 weeks> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1\~2 : 5-FU 1200mg/m2 IVF for 24hours
Study NCT00625261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heidelberg Parent-based Language Intervention HPLI
Description: The HPLI is a group program for parents of young children with language delay. This 12-14week program includes seven two-our sessions and one three-our session six months later. It is designed for 5 to 10 people and based of an interactive model of language intervention, wich presumes that optimized parental input will provide better language-learning opportunities.